Clinical Ophthalmology (Dec 2021)

Evaluation of Same-Day versus Next-Day Implantation of Intracanalicular Dexamethasone for the Control of Postoperative Inflammation and Pain Following Cataract Surgery

  • Saenz B,
  • Ferguson TJ,
  • Abraham N,
  • Mueller BH,
  • Parkhurst GD

Journal volume & issue
Vol. Volume 15
pp. 4615 – 4620

Abstract

Read online

Bobby Saenz,1 Tanner J Ferguson,2 Noelle Abraham,1 Brett H Mueller,1 Gregory D Parkhurst1 1Parkhurst NuVision, San Antonio, TX, USA; 2Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USACorrespondence: Bobby SaenzParkhurst NuVision, 9725 Datapoint, Suite 106, San Antonio, TX, 78229, USATel +1-210-585-2020Email [email protected]: To evaluate the safety and efficacy of a sustained-release intracanalicular dexamethasone insert for postoperative inflammation and pain implanted in a clinical setting preoperatively or on postoperative day 1.Methods: Single-site, retrospective, contralateral eye study of patients undergoing cataract surgery. Included were subjects with a dexamethasone intracanalicular insert implanted in the clinic immediately prior to surgery in one eye (same-day) and on postoperative day 1 (POD1) in the contralateral eye. The primary outcome measure was the resolution of anterior chamber inflammation at 1 week postoperative. Secondary outcome measures included proportion of eyes requiring additional therapy for pain and inflammation through 1 month as well as the number of eyes with IOP spikes above baseline. Safety measures included adverse events through 1 month postoperative.Results: Sixty-two eyes of 31 subjects were included in the case series. At 1 week postoperative, 52% of the eyes (n = 16) achieved complete resolution of inflammation in the same-day group and 58% (n = 18) met this endpoint at 1 week in the POD1 group. One subject in the same-day group required additional therapy for rebound inflammation and no eyes required additional therapy in the POD1 group. There were no reports of pain at 1 week or 1 month in either group. There were no implant-related adverse events in either group.Conclusion: The favorable results of this study indicate that the sustained-release dexamethasone insert can be safely implanted in the clinic either preoperatively on the day of surgery or on postoperative day 1 for the control of pain and inflammation following cataract surgery.Keywords: cataract surgery, dexamethasone, intracanalicular, ocular inflammation, ocular pain

Keywords